IAMBIC
LIVE

Serial Number

97905499

Owner

Entos, Inc.

Attorney

Alyssa M. Worsham

Filing Date

Apr 25, 2023

Add to watchlist:

No watchlists yet
View on USPTO

IAMBIC Trademark

Serial Number: 97905499 • Registration: 7977151

IAMBIC is a trademark filed by Entos, Inc. on April 25, 2023. The trademark is classified under Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Entos, Inc. (4 trademarks)

Los Angeles, CA 90027

Entity Type: 03

Iambic Therapeutics, Inc. (5 trademarks)

5627 Oberlin Drive, Suite 120
San Diego, CA 92121

Entity Type: 03

Trademark Details

Filing Date

April 25, 2023

Registration Date

October 7, 2025

Published for Opposition

November 5, 2024

Goods & Services

research and development in the field of computational biology, bioinformatics, and genomics; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; pharmaceutical, medical, scientific, biotechnology, and biopharmaceutical research and development; technical scientific consultation and product development for others in the field of biotechnology and immunology; development of pharmaceuticals; research and development of pharmaceutical preparations and substances for use in clinical trials; scientific and technological services, namely, research and design in the field of computational chemistry, machine learning and artificial intelligence for use in chemistry, biology, physics, biochemistry, chemical engineering, and computer science, and design and optimization of molecules, materials, and drugs; chemistry services, namely, laboratory research in the fields of chemistry and design of new chemistry; chemistry services in the nature of drug, and molecular discovery services, and product development services; chemical research and chemistry consultation in the field of drug and molecular development; industrial analysis and research services being scientific research in the field of drug, materials, and molecular development; technical data analysis services being technology advisory services relating to computer programs for use in chemistry, biology, physics, biochemistry, chemical engineering, computer science, and the discovery of new molecules, materials, drugs, and machine learning techniques; computer programming in the fields of molecular, materials, and drug development; computer consultancy services being computer software consultation in the field of drug, materials, and molecular development; computer software consultation services, namely, assistance and consulting in connection with the development of computer applications, databases and systems for use in the field of drug, materials, and molecular development; consulting services in the design and implementation of computer-based information systems for business, namely, provision of online information relating to computer hardware and software design in the field of drug, materials, and molecular development; creation, maintenance, hosting, and design of websites in the field of drug, materials, and molecular development; provision of online non-downloadable software for simulations for drug, materials, and molecular discovery; software as a service (SAAS) services featuring computer software platforms for use in optimizing drug, materials, and molecular discovery; platform as a service (PAAS) featuring computer software platforms for use in optimizing drug, materials, and molecular discovery; creating website based indexes of information for others using information technology for use in the field of drug, materials, and molecular development; computer graphics design services, namely, realization of computer graphics and digital imaging for use in the field of drug, materials, and molecular development; scientific research in connection with computerized automation of technical processes for use in the field of drug, materials, and molecular development; software as a services (SAAS) services in the nature of hosting cloud-based computing featuring software for optimizing the development of new molecules and designing and discovering molecules, drugs, battery materials, and other molecular products

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Oct 7, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Oct 7, 2025 R.PR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Oct 3, 2025 NRCC
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Sep 16, 2025 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Sep 16, 2025 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Sep 16, 2025 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Sep 16, 2025 AITU
USE AMENDMENT FILED
Apr 23, 2025 IUAF
TEAS STATEMENT OF USE RECEIVED
Apr 23, 2025 EISU
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Dec 17, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 5, 2024 NPUB
PUBLISHED FOR OPPOSITION
Nov 5, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 16, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 25, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 13, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 13, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 13, 2024 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Jul 16, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Jul 16, 2024 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 17, 2024 GNRN
NON-FINAL ACTION E-MAILED
Apr 17, 2024 GNRT
NON-FINAL ACTION WRITTEN
Apr 17, 2024 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 1, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 1, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 1, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 23, 2024 GNRN
NON-FINAL ACTION E-MAILED
Jan 23, 2024 GNRT
NON-FINAL ACTION WRITTEN
Jan 23, 2024 CNRT
ASSIGNED TO EXAMINER
Jan 23, 2024 DOCK
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Jun 28, 2023 ASGN
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 23, 2023 NWOS
NEW APPLICATION ENTERED
Apr 28, 2023 NWAP